James Investment Research Inc. acquired a new stake in LivaNova PLC (NASDAQ:LIVN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 24,920 shares of the company’s stock, valued at approximately $1,992,000. James Investment Research Inc. owned 0.05% of LivaNova as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in LIVN. Prudential Financial Inc. raised its position in LivaNova by 21.3% during the second quarter. Prudential Financial Inc. now owns 29,552 shares of the company’s stock worth $1,809,000 after acquiring an additional 5,180 shares during the last quarter. Alliancebernstein L.P. acquired a new position in LivaNova during the second quarter worth about $4,357,000. Riverhead Capital Management LLC raised its position in LivaNova by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock worth $108,000 after acquiring an additional 763 shares during the last quarter. Teachers Advisors LLC acquired a new position in LivaNova during the second quarter worth about $5,362,000. Finally, TIAA CREF Investment Management LLC raised its position in LivaNova by 642.0% during the second quarter. TIAA CREF Investment Management LLC now owns 130,852 shares of the company’s stock worth $8,009,000 after acquiring an additional 113,216 shares during the last quarter. Hedge funds and other institutional investors own 88.53% of the company’s stock.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $82.15, for a total value of $82,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alfred J. Novak sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $85.77, for a total transaction of $171,540.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,830 shares of company stock valued at $576,920. Insiders own 0.28% of the company’s stock.
A number of brokerages have issued reports on LIVN. Needham & Company LLC lifted their target price on shares of LivaNova to $93.00 and gave the stock a “buy” rating in a research report on Tuesday, November 21st. Canaccord Genuity restated a “hold” rating and set a $76.00 target price on shares of LivaNova in a research report on Tuesday, November 14th. BidaskClub cut shares of LivaNova from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. Zacks Investment Research upgraded shares of LivaNova from a “hold” rating to a “buy” rating and set a $89.00 price target for the company in a report on Thursday, November 9th. Finally, BTIG Research reiterated a “hold” rating on shares of LivaNova in a report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $79.71.
Shares of LivaNova PLC (NASDAQ LIVN) opened at $82.16 on Tuesday. The company has a market cap of $3,967.81, a PE ratio of 70.22, a PEG ratio of 2.44 and a beta of 0.83. LivaNova PLC has a twelve month low of $45.67 and a twelve month high of $88.56. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/24920-shares-in-livanova-plc-livn-acquired-by-james-investment-research-inc.html.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.